Patents by Inventor Jonathan Rohll

Jonathan Rohll has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100273996
    Abstract: A method of producing a replication defective retrovirus comprising transfecting a producer cell with the following: iii) a retroviral genome; iv) a nucleotide sequence coding for retroviral gag and pot proteins; and iii) nucleotide sequences encoding other essential viral packaging components not encoded by the nucleotide sequence of (ii); characterised in that the nucleotide sequence coding for retroviral gag and pot proteins is codon optimised for expression in the producer cell.
    Type: Application
    Filed: October 2, 2009
    Publication date: October 28, 2010
    Inventors: Alan John Kingsman, Narry Kim, Ekaterini Kotsopoulou, Jonathan Rohll, Kyriacos A. Mitrophanous
  • Publication number: 20090111106
    Abstract: The present invention provides a vector system comprising a mutated post-transcriptional regulatory element. In particular, the present invention relates to a mutated WPRE sequence that can efficiently express nucleotides of interest in a retroviral vector system. The present invention also relates to methods of delivering and expressing nucleotides of interest to a target cell.
    Type: Application
    Filed: July 7, 2008
    Publication date: April 30, 2009
    Inventors: Kyri Mitrophanous, Jonathan Rohll, James Miskin, Susan Mary Kingsman
  • Publication number: 20080269473
    Abstract: A method of producing a replication defective retrovirus comprising transfecting a producer cell with the following: iii) a retroviral genome; iv) a nucleotide sequence coding for retroviral gag and pol proteins; and iii) nucleotide sequences encoding other essential viral packaging components not encoded by the nucleotide sequence of (ii); characterised in that the nucleotide sequence coding for retroviral gag and pol proteins is codon optimised for expression in the producer cell.
    Type: Application
    Filed: March 20, 2008
    Publication date: October 30, 2008
    Inventors: Alan John Kingsman, Narry Kim, Ekaterini Kotsopoulou, Jonathan Rohll, Kyriacos A. Mitrophanous
  • Patent number: 7419829
    Abstract: The present invention provides a vector system comprising a mutated post-transcriptional regulatory element. In particular, the present invention relates to a mutated WPRE sequence that can efficiently express nucleotides of interest in a retroviral vector system. The present invention also relates to methods of delivering and expressing nucleotides of interest to a target cell.
    Type: Grant
    Filed: June 21, 2004
    Date of Patent: September 2, 2008
    Assignee: Oxford BioMedica (UK) Limited
    Inventors: Kyri Mitrophanous, Jonathan Rohll, James Miskin, Susan Marie Kingsman
  • Patent number: 7259015
    Abstract: Provided are retroviral vector genomes and vector systems comprising the genomes. In particular, a retroviral vector genome comprising two or more NOIs, operably linked by one or more Internal Ribosome Entry Site(s); a lentiviral vector genome comprising two or more NOIs suitable for treating a neurodegenerative disorder; and a lentiviral vector genome which encodes tyrosine hydroxylase, GTP-cyclohydrolase I and, optionally, Aromatic Amino Acid Dopa Decarboxylase are provided.
    Type: Grant
    Filed: April 7, 2003
    Date of Patent: August 21, 2007
    Assignee: Oxford Biomedia (UK) Limited
    Inventors: Alan John Kingsman, Nicholas D. Mazarakis, Enca Martin-Rendon, Mimoun Azzouz, Jonathan Rohll
  • Publication number: 20070025970
    Abstract: The present invention relates to retroviral vector genomes and to vector systems comprising such genomes. In particular the present invention relates to a retroviral vector genome comprising two or more NOIs operably linked by one or more Internal Ribosome Entry Site(s); a lentiviral vector genome comprising two or more NOIs suitable for treating a neurodegenerative disorder; and a lentiviral vector genome which encodes tyrosine hydroxylase, GTP-cyclohydrolase I and optionally Aromatic Amino Acid Dopa Decarboxylase.
    Type: Application
    Filed: July 14, 2006
    Publication date: February 1, 2007
    Inventors: Alan Kingsman, Nicholas Mazarakis, Enca Martin-Rendon, Mimoun Azzouz, Jonathan Rohll
  • Publication number: 20060024274
    Abstract: A retroviral vector derived from a non-primate lentivirus genome comprising a deleted gag gene wherein the deletion in gag removes one or more nucleotides downstream of nucleotide 350 of the gag coding sequence.
    Type: Application
    Filed: June 15, 2005
    Publication date: February 2, 2006
    Inventors: Alan Kingsman, Miles Carroll, Jonathan Rohll, Kyriacos Mitrophanous, Narry Kim
  • Patent number: 6969598
    Abstract: A method for producing viral vectors is described using packaging and producer cell lines is described. The producer cell comprises: (i) a first nucleotide sequence (NS) encoding a toxic viral envelope protein operably linked to a promoter; wherein the promoter is operably linked to at least one copy of a TRE; (ii) a second NS wherein the second NS comprises a sequence encoding a tetracycline modulator; (iii) a third NS encoding a retrovirus nucleocapsid protein; and (iv) a fourth NS comprising a retroviral sequence capable of being encapsidated in the nucleocapsid protein such that the retroviral vector particle titre obtainable from the producer cell is regulatable by tetracycline and an initial stimulus with sodium butyrate or functional analogues thereof.
    Type: Grant
    Filed: April 30, 2002
    Date of Patent: November 29, 2005
    Assignees: Oxford Biomedica (UK) Limited, The University of North Carolina at Chapel Hill
    Inventors: John C. Olsen, Kyriacos Andreou Mitrophanous, Jonathan Rohll, Alan John Kingsman, Fiona Margaret Ellard
  • Publication number: 20050260164
    Abstract: Provided is an improved method for controlling gene expression in vivo through the use of a gene switch comprising one or more aptamer sequences operably linked to or incorporated into the untranslated regions (UTRs) of a transgene or nucleotide sequence of interest. Also provided are expression vectors having aptamer sequences located within the 3? UTR, the 5? UTR and between the genes of a multicistronic mRNA, as well as methods of using the expression vectors for controlling or regulating gene expression.
    Type: Application
    Filed: April 8, 2005
    Publication date: November 24, 2005
    Inventors: Doug Jolly, Jonathan Rohll, Bernd Buehler, Kyri Mitrophanous, Pippa Radcliffe
  • Publication number: 20050042234
    Abstract: Provided herein are methods for producing a replication defective retrovirus, which comprises transfecting a producer cell with (1) a retroviral genome; (2) a nucleotide sequence coding for retroviral gag and pol proteins that is codon-optimized for expression in the producer cell; and (3) nucleotide sequences encoding other essential viral packaging components not encoded by the nucleotide sequence of (1).
    Type: Application
    Filed: April 18, 2001
    Publication date: February 24, 2005
    Inventors: Alan Kingsman, Narry Kim, Ekaterini Kotsopoulou, Jonathan Rohll, Kyriacos Mitrophanous
  • Publication number: 20050002907
    Abstract: The present invention provides a vector system comprising a mutated post-transcriptional regulatory element. In particular, the present invention relates to a mutated WPRE sequence that can efficiently express nucleotides of interest in a retroviral vector system. The present invention also relates to methods of delivering and expressing nucleotides of interest to a target cell.
    Type: Application
    Filed: June 21, 2004
    Publication date: January 6, 2005
    Inventors: Kyri Mitrophanous, Jonathan Rohll, James Miskin, Susan Kingsman
  • Publication number: 20040013648
    Abstract: Provided are retroviral vector genomes and vector systems comprising the genomes. In particular, a retroviral vector genome comprising two or more NOIs, operably linked by one or more Internal Ribosome Entry Site(s); a lentiviral vector genome comprising two or more NOIs suitable for treating a neurodegenerative disorder; and a lentiviral vector genome which encodes tyrosine hydroxylase, GTP-cyclohydrolase I and, optionally, Aromatic Amino Acid Dopa Decarboxylase are provided.
    Type: Application
    Filed: April 7, 2003
    Publication date: January 22, 2004
    Inventors: Alan John Kingsman, Nicholas D. Mazarakis, Enca Martin-Rendon, Mimoun Azzouz, Jonathan Rohll
  • Publication number: 20030147907
    Abstract: A retroviral vector derived from a non-primate lentivirus genome comprising a deleted gag gene wherein the deletion in gag removes one or more nucleotides downstream of nucleotide 350 of the gag coding sequence.
    Type: Application
    Filed: May 29, 2001
    Publication date: August 7, 2003
    Inventors: Alan John Kingsman, Miles William Carroll, Jonathan Rohll, Kyriacos Mitrophanous, Narry Kim
  • Publication number: 20030143205
    Abstract: An alpha-lentivirus vector comprising at least one alphaviral component and at least one lentiviral component, wherein the lentiviral component is capable of being packaged into a lentiviral particle after introduction of said vector into a human cell.
    Type: Application
    Filed: July 22, 2002
    Publication date: July 31, 2003
    Applicant: Oxford Biomedica (UK) Limited
    Inventors: Jason Slingsby, Kyriacos Mitrophanous, Jonathan Rohll, Alison Lawrie
  • Publication number: 20030113898
    Abstract: A method for producing viral vectors is described using packaging and producer cell lines is described. The producer cell comprises: (i) a first nucleotide sequence (NS) encoding a toxic viral envelope protein operably linked to a promoter; wherein the promoter is operably linked to at least one copy of a TRE; (ii) a second NS wherein the second NS comprises a sequence encoding a tetracycline modulator; (iii) a third NS encoding a retrovirus nucleocapsid protein; and (iv) a fourth NS comprising a retroviral sequence capable of being encapsidated in the nucleocapsid protein such that the retroviral vector particle titre obtainable from the producer cell is regulatable by tetracycline and an initial stimulus with sodium butyrate or functional analogues thereof.
    Type: Application
    Filed: April 30, 2002
    Publication date: June 19, 2003
    Applicant: Oxford Biomedica (UK) Limited
    Inventors: John C. Olsen, Kyriacos Andreou Mitrophanous, Jonathan Rohll, Alan John Kingsman, Fiona Margaret Ellard
  • Publication number: 20020034393
    Abstract: A retroviral vector capable of delivering an NOI and comprising an exogenous second synthesis element.
    Type: Application
    Filed: May 18, 2001
    Publication date: March 21, 2002
    Inventors: Kyriacos A. Mitrophanous, Mark Uden, Jonathan Rohll, Susan Mary Kingsman, Alan John Kingsman
  • Patent number: 6312683
    Abstract: A retroviral vector derived from a non-primate lentivirus genome comprising a deleted gag gene wherein the deletion in gag removes one or more nucleotides downstream of nucleotide 350 of the gag coding sequence.
    Type: Grant
    Filed: January 27, 1999
    Date of Patent: November 6, 2001
    Assignee: Oxford Biomedica (UK) Limited
    Inventors: Alan John Kingsman, Miles William Carroll, Jonathan Rohll, Kyriacos Mitrophanous, Narry Kim